Table 1 Patient characteristics in the imatinib and non-imatinib groups

Number of patients

62(75.6%)

20(24.4%)

Age (y), median (range)

29(6-50)

27.5(3-51)

0.256

<30 / >30 y

37/25

10/10

0.604

Sex (M/F)

43/19

12/8

0.071

Disease status pre-HCT

CR1/ >CR1

50/12

16/4

1.000

Additional cytogenetic

abnormality

Yes/No

3/59

1/19

0.272

Imatinib therapy before HCT

Yes/ No

54/8

14/6

0.180

RT-PCR-BCR/ABL(pre-HCT)

0/ >0

26/36

6/14

0.752

Donor type

HLA matched siblings

15

4

0.199

MMR

45

15

MUD

2

1

Stem-cell source

PBSCT

7

2

1.000

BMT + PBSCT

55

18

Conditioning regimen

BUCY

62

17

0.013

TBI/CY

0

3

Engraftment

Myeloid (day),median(range)

13(10-22)

13(10-27)

0.248

Platelet (day),median(range)

17(9-150)

13(7-30)

0.268

RT-PCR-BCR/ABL(post-HCT)

0/ >0

48/ 14

18/ 2

0.540

Acute GVHD

0/ I°-II°/ III-IV°

30/ 28/ 4

5/ 11/ 4

0.199

Chronic GVHD

no/ L/ E-cGVHD

22/ 25/ 12

3/ 8/ 8

0.223